Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
McKinsey
Boehringer Ingelheim
Moodys
Harvard Business School

Last Updated: January 20, 2020

DrugPatentWatch Database Preview

Patent: 9,161,935

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 9,161,935
Title:Use of laquinimod for treating Crohn\'s disease patients who failed first-line anti-TNF therapy
Abstract: This application provides for a method of treating a human patient afflicted with anti-TNF.alpha. refractory Crohn\'s disease, of treating a human patient afflicted with non-fibrostenotic Crohn\'s disease, and of treating a human patient whose Crohn\'s disease had not been surgically treated, the method comprising periodically administering to the patient an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the patient. This application also provides for a method of inducing or maintaining clinical remission in a human patient afflicted with Crohn\'s disease comprising periodically administering to the patient an amount of laquinimod effective to induce or maintain clinical remission in the patient, which amount of laquinimod is less than 0.5 mg/day.
Inventor(s): Tarcic; Nora (Modiin, IL), Haviv; Asi (Kvutsat Shiller, IL), Blaugrund; Eran (Rehovot, IL), Kaye; Joel (Netanya, IL)
Assignee: TEVA PHARMACEUTICAL INDUSTRIES, LTD. (Petach-Tikva, IL)
Application Number:13/757,004
Patent Claims:see list of patent claims

Details for Patent 9,161,935

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23   Start Trial TEVA PHARMACEUTICAL INDUSTRIES, LTD. (Petach-Tikva, IL) 2032-02-03 RX search
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial TEVA PHARMACEUTICAL INDUSTRIES, LTD. (Petach-Tikva, IL) 2032-02-03 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Express Scripts
Medtronic
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.